https://investors.immunome.com/ 2026-01-08T20:10:44+00:00 https://investors.immunome.com/opt-out-preferences/ 2025-11-18T21:07:42+00:00 https://investors.immunome.com/board-of-directors/ 2025-06-26T17:06:47+00:00 https://investors.immunome.com/investor-contacts/ 2025-05-27T18:40:08+00:00 https://investors.immunome.com/committee-composition/ 2025-06-26T17:05:59+00:00 https://investors.immunome.com/investor-email-alerts/ 2026-01-27T18:06:35+00:00 https://investors.immunome.com/governance-documents/ 2026-01-15T17:07:03+00:00 https://investors.immunome.com/sec-filings/ 2025-05-27T18:36:27+00:00 https://investors.immunome.com/stock-info/ 2025-06-10T20:28:05+00:00 https://investors.immunome.com/presentations/ 2025-11-11T16:20:57+00:00 https://investors.immunome.com/events/ 2025-12-02T19:07:10+00:00 https://investors.immunome.com/news-releases/ 2025-12-02T19:01:27+00:00 https://investors.immunome.com/event/h-c-wainwright-28th-annual-global-investment-conference/ 2026-08-14T20:27:49+00:00 https://investors.immunome.com/immunome-reports-second-quarter-2026-financial-results-and-provides-business-update/ 2026-08-11T20:02:14+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-23/ 2026-08-06T20:02:20+00:00 https://investors.immunome.com/immunome-announces-first-patient-dosed-in-phase-1-trial-evaluating-im-3050-an-fap-targeted-radioligand-therapy-in-patients-with-fap-expressing-advanced-solid-tumors/ 2026-07-20T11:30:33+00:00 https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/ 2026-07-08T11:30:33+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22/ 2026-07-07T20:02:06+00:00 https://investors.immunome.com/immunome-announces-first-patient-dosed-in-phase-1-trial-evaluating-im-1617-a-potential-first-in-class-adc-in-patients-with-advanced-solid-tumors/ 2026-06-11T11:30:27+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-21/ 2026-06-04T20:02:24+00:00 https://investors.immunome.com/immunome-announces-detailed-phase-3-ringside-data-for-varegacestat-in-adults-with-progressing-desmoid-tumors-at-the-2026-asco-annual-meeting/ 2026-05-30T12:00:14+00:00 https://investors.immunome.com/immunome-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference/ 2026-05-27T12:00:56+00:00 https://investors.immunome.com/event/goldman-sachs-47th-annual-global-healthcare-conference/ 2026-05-26T20:23:54+00:00 https://investors.immunome.com/immunome-reports-first-quarter-2026-financial-results-and-provides-business-update/ 2026-05-12T20:02:21+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-20/ 2026-05-05T20:00:25+00:00 https://investors.immunome.com/immunome-announces-submission-of-new-drug-application-to-u-s-fda-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/ 2026-04-29T11:30:24+00:00 https://investors.immunome.com/immunome-announces-oral-presentation-of-phase-3-ringside-data-at-2026-asco-annual-meeting/ 2026-04-21T14:30:24+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-19/ 2026-04-02T20:00:11+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-18/ 2026-03-05T21:00:20+00:00 https://investors.immunome.com/immunome-reports-full-year-2025-financial-results-and-provides-business-update/ 2026-03-03T21:02:13+00:00 https://investors.immunome.com/immunome-to-present-at-upcoming-investor-conferences-3/ 2026-02-23T13:00:35+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-17/ 2026-02-05T21:00:12+00:00 https://investors.immunome.com/immunome-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026/ 2026-02-04T13:01:00+00:00 https://investors.immunome.com/event/leerink-partners-global-healthcare-conference/ 2026-01-29T14:21:20+00:00 https://investors.immunome.com/event/td-cowen-46th-annual-health-care-conference/ 2026-01-29T14:21:11+00:00 https://investors.immunome.com/event/guggenheims-emerging-outlook-biotech-summit-2026/ 2026-01-21T14:05:09+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-16/ 2026-01-08T21:05:20+00:00 https://investors.immunome.com/immunome-to-present-at-44th-annual-j-p-morgan-healthcare-conference/ 2026-01-06T13:00:50+00:00 https://jpmorgan.metameetings.net/events/healthcare26/sessions/317355-immunome-inc/webcast?gpu_only=true 2026-01-14T17:34:46+00:00 https://investors.immunome.com/immunome-announces-pricing-of-public-offering-of-common-stock-2/ 2025-12-17T01:16:08+00:00 https://investors.immunome.com/immunome-announces-proposed-public-offering-of-common-stock-3/ 2025-12-15T21:01:30+00:00 https://investors.immunome.com/immunome-announces-positive-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/ 2025-12-15T12:00:34+00:00 https://investors.immunome.com/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors/ 2025-12-14T21:00:20+00:00 https://investors.immunome.com/event/phase-3-ringside-trial-topline-results-for-varegacestat/ 2025-12-14T20:59:48+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15/ 2025-12-04T21:05:29+00:00 https://investors.immunome.com/immunome-to-present-at-upcoming-investor-conferences-2/ 2025-11-25T13:00:44+00:00 https://investors.immunome.com/event/8th-annual-evercore-healthcare-conference/ 2025-11-20T18:39:47+00:00 https://investors.immunome.com/event/piper-sandler-37th-annual-healthcare-conference/ 2025-11-20T18:36:40+00:00 https://investors.immunome.com/immunome-reports-third-quarter-2025-financial-results-and-provides-business-update/ 2025-11-18T19:56:01+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14/ 2025-11-18T19:56:01+00:00 https://investors.immunome.com/immunome-to-present-at-2nd-annual-guggenheim-healthcare-innovation-conference/ 2025-11-18T19:56:01+00:00 https://investors.immunome.com/immunome-presents-preclinical-data-showing-proprietary-top1i-adc-payload-hc74-overcomes-multiple-mechanisms-of-adc-resistance/ 2025-11-18T19:56:01+00:00 https://investors.immunome.com/event/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ 2025-10-23T16:55:56+00:00 https://investors.immunome.com/event/guggenheim-2nd-annual-healthcare-innovation-conference/ 2025-10-07T18:10:33+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13/ 2025-11-18T19:56:01+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-12/ 2025-11-18T19:56:01+00:00 https://investors.immunome.com/immunome-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference/ 2025-11-18T19:56:01+00:00 https://investors.immunome.com/event/1495/ 2025-08-11T18:07:26+00:00 https://investors.immunome.com/immunome-reports-second-quarter-2025-financial-results-and-provides-business-update/ 2025-08-07T17:16:30+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-11/ 2025-08-07T17:17:09+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-10/ 2025-08-07T17:17:41+00:00 https://investors.immunome.com/event/2025-asco-annual-meeting/ 2025-07-08T16:13:18+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-9/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/event/td-cowen-investor-conference/ 2025-05-27T19:38:29+00:00 https://investors.immunome.com/event/leerinks-global-biopharma-conference/ 2025-05-27T19:36:14+00:00 https://investors.immunome.com/event/1170/ 2025-05-27T19:26:05+00:00 https://investors.immunome.com/event/td-cowen-6th-annual-oncology-innovation-summit/ 2025-05-27T19:23:27+00:00 https://investors.immunome.com/event/goldman-sachs-46th-annual-global-heathcare-conference-2025/ 2025-05-27T19:17:49+00:00 https://investors.immunome.com/immunome-to-present-at-upcoming-investor-conferences/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-reports-first-quarter-2025-financial-results-and-provides-business-update/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-8/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-to-present-at-the-24th-annual-needham-virtual-healthcare-conference/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-7/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-reports-full-year-2024-financial-results-and-provides-business-update/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-doses-first-patient-in-phase-1-trial-of-im-1021-a-ror1-targeted-adc/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-to-present-at-upcoming-march-conferences/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-5/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-announces-closing-of-upsized-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-announces-pricing-of-upsized-public-offering-of-common-stock/ 2025-06-05T21:00:08+00:00 https://investors.immunome.com/immunome-announces-proposed-public-offering-of-common-stock-2/ 2025-06-05T21:00:09+00:00 https://investors.immunome.com/immunome-provides-pipeline-update-in-advance-of-presentation-at-the-43rd-annual-j-p-morgan-healthcare-conference/ 2025-06-05T21:00:09+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-4/ 2025-06-05T21:00:09+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-3/ 2025-06-05T21:00:09+00:00 https://investors.immunome.com/immunome-to-present-at-the-piper-sandler-36th-annual-healthcare-conference/ 2025-06-05T21:00:09+00:00 https://investors.immunome.com/immunome-reports-third-quarter-2024-financial-results-and-provides-business-update/ 2025-06-05T21:00:09+00:00 https://investors.immunome.com/immunome-to-present-at-guggenheims-inaugural-healthcare-innovation-conference/ 2025-06-05T21:00:09+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-presents-compelling-preclinical-data-demonstrating-robust-anti-tumor-activity-for-im-1021/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-to-present-poster-highlighting-preclinical-evaluation-of-im-1021-a-ror1-targeted-antibody-drug-conjugate-at-the-36th-eortc-nci-aacr-symposium/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-appoints-roee-shahar-as-executive-vice-president-commercial/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-to-present-updated-results-for-ringside-phase-2-trial-of-al102-for-the-treatment-of-desmoid-tumors-at-the-european-society-for-medical-oncology-esmo-congress-2024/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-to-present-at-morgan-stanley-22nd-annual-global-healthcare-conference/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-reports-second-quarter-2024-financial-results-and-provides-business-update/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-provides-update-on-recent-business-development-activity-expected-to-expand-adc-capabilities/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-appoints-phil-tsai-as-chief-technical-officer/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-announces-completion-of-purchase-of-assets-from-atreca/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-announces-promotion-of-max-rosett-to-chief-financial-officer/ 2025-06-05T21:00:48+00:00 https://investors.immunome.com/immunome-reports-first-quarter-2024-financial-results-and-provides-business-update/ 2025-06-05T21:00:49+00:00 https://investors.immunome.com/immunome-to-present-at-2024-bank-of-america-healthcare-conference/ 2025-06-05T21:00:49+00:00 https://investors.immunome.com/immunome-appoints-kinney-horn-as-chief-business-officer/ 2025-06-05T21:00:49+00:00 https://investors.immunome.com/immunome-appoints-sandra-m-swain-to-board-of-directors/ 2025-06-05T21:00:49+00:00 https://investors.immunome.com/immunome-to-present-preclinical-data-for-im-3050-its-lead-radioligand-therapy-candidate-at-2024-american-association-for-cancer-research-aacr-annual-meeting/ 2025-08-07T18:02:00+00:00 https://investors.immunome.com/immunome-reports-full-year-2023-financial-results-and-provides-update-on-recently-acquired-assets/ 2025-08-07T18:02:14+00:00 https://investors.immunome.com/immunome-completes-acquisition-of-al102-a-phase-3-asset-for-the-treatment-of-desmoid-tumors-from-ayala/ 2025-08-07T18:02:27+00:00 https://investors.immunome.com/immunome-to-participate-in-the-leerink-partners-global-biopharma-conference/ 2025-08-07T18:02:44+00:00 https://investors.immunome.com/immunome-to-participate-in-the-td-cowen-44th-annual-healthcare-conference/ 2025-08-07T18:03:00+00:00 https://investors.immunome.com/immunome-recognizes-ayala-pharmaceuticals-announced-completion-of-enrollment-in-phase-3-ringside-study-evaluating-al102-in-desmoid-tumors/ 2025-08-07T18:03:57+00:00 https://investors.immunome.com/immunome-announces-closing-of-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares/ 2025-08-07T18:03:58+00:00 https://investors.immunome.com/immunome-announces-pricing-of-public-offering-of-common-stock/ 2025-08-07T18:03:59+00:00 https://investors.immunome.com/immunome-announces-proposed-public-offering-of-common-stock/ 2025-08-07T18:04:00+00:00 https://investors.immunome.com/immunome-to-acquire-al102-a-phase-3-asset-for-the-treatment-of-desmoid-tumors-from-ayala-pharmaceuticals/ 2025-08-07T18:04:01+00:00 https://investors.immunome.com/immunome-to-present-at-the-guggenheim-healthcare-talks-6th-annual-biotechnology-conference/ 2025-08-07T18:04:02+00:00 https://investors.immunome.com/immunome-exclusively-licenses-zentalis-ror1-antibody-drug-conjugate-and-proprietary-technology-platform/ 2025-08-07T18:04:03+00:00 https://investors.immunome.com/immunome-appoints-phil-roberts-as-chief-technical-officer/ 2025-08-07T18:04:05+00:00 https://investors.immunome.com/immunome-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference/ 2025-08-07T18:04:06+00:00 https://investors.immunome.com/immunome-appoints-carol-a-schafer-to-board-of-directors/ 2025-08-07T18:04:07+00:00 https://investors.immunome.com/immunome-to-acquire-antibody-related-assets-and-materials-from-atreca/ 2024-12-17T20:16:46+00:00 https://investors.immunome.com/immunome-to-present-at-the-stifel-2023-healthcare-conference/ 2024-12-17T20:16:59+00:00 https://investors.immunome.com/immunome-reports-third-quarter-2023-financial-results/ 2024-12-17T20:17:01+00:00 https://investors.immunome.com/immunome-appoints-jean-jacques-bienaim-to-board-of-directors/ 2024-12-17T20:17:02+00:00 https://investors.immunome.com/immunome-appoints-bob-lechleider-m-d-as-chief-medical-officer/ 2024-12-17T20:17:14+00:00 https://investors.immunome.com/immunome-and-morphimmune-announce-successful-completion-of-merger-with-125-million-pipe-to-develop-novel-targeted-cancer-therapies/ 2024-12-17T20:17:15+00:00 https://investors.immunome.com/immunome-reports-second-quarter-2023-financial-results/ 2024-12-17T20:17:28+00:00 https://investors.immunome.com/immunome-and-morphimmune-announce-definitive-merger-agreement-and-simultaneous-private-placement-investment-of-125-million-to-develop-targeted-cancer-therapies/ 2023-07-03T14:30:19+00:00 https://investors.immunome.com/immunome-publishes-preclinical-research-demonstrating-that-inhibition-of-il-38-using-an-antibody-leads-to-anti-tumor-activity/ 2024-12-17T20:17:47+00:00 https://investors.immunome.com/immunome-reports-first-quarter-2023-financial-results/ 2024-12-17T20:17:48+00:00 https://investors.immunome.com/immunome-reports-fourth-quarter-and-full-year-2022-financial-results/ 2024-12-17T20:18:02+00:00 https://investors.immunome.com/immunome-to-present-at-13th-annual-world-adc-london-conference/ 2024-12-17T20:18:04+00:00 https://investors.immunome.com/immunome-announces-formation-of-antibody-drug-conjugate-and-t-cell-redirection-advisory-board/ 2024-12-17T20:18:15+00:00 https://investors.immunome.com/abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-targets/ 2024-12-17T20:18:27+00:00 https://investors.immunome.com/immunome-reports-third-quarter-2022-financial-results/ 2022-11-14T13:10:23+00:00 https://investors.immunome.com/immunome-presents-preclinical-data-on-novel-anti-epn1-antibody-imm20059-at-the-society-for-immunotherapy-of-cancers-sitc-37th-annual-meeting-2/ 2022-11-09T17:04:10+00:00 https://investors.immunome.com/immunome-presents-preclinical-data-on-novel-anti-epn1-antibody-imm20059-at-the-society-for-immunotherapy-of-cancers-sitc-37th-annual-meeting/ 2022-11-07T13:17:10+00:00 https://investors.immunome.com/immunome-announces-publication-in-clinical-translational-immunology-highlighting-b-cell-repertoires-in-patients-with-breast-cancer/ 2022-08-23T13:02:02+00:00 https://investors.immunome.com/immunome-reports-second-quarter-2022-financial-results/ 2022-08-05T12:01:49+00:00 https://investors.immunome.com/immunomes-covid-19-cocktail-retains-neutralizing-activity-against-the-most-prevalent-omicron-subvariants-in-the-us-ba-4-5-and-ba-2-12-1/ 2022-07-06T12:05:40+00:00 https://investors.immunome.com/immunome-announces-initiation-of-phase-1b-study-of-imm-bcp-01-for-the-treatment-of-covid-19/ 2022-06-09T12:06:00+00:00 https://investors.immunome.com/immunome-to-present-at-the-jefferies-healthcare-conference/ 2022-06-02T12:07:42+00:00 https://investors.immunome.com/immunome-provides-research-development-update-on-lead-oncology-candidate-targeting-il-38/ 2022-05-23T12:09:36+00:00 https://investors.immunome.com/immunome-announces-data-demonstrating-covid-19-antibody-cocktail-potently-clears-omicron-ba-1-variant-in-hamster-model-and-retains-activity-against-ba-2-subvariant/ 2022-05-19T12:03:41+00:00 https://investors.immunome.com/immunome-reports-first-quarter-2022-financial-results/ 2022-05-12T12:04:21+00:00 https://investors.immunome.com/immunome-reports-fourth-quarter-and-full-year-2021-financial-results/ 2022-03-28T12:07:58+00:00 https://investors.immunome.com/fda-lifts-clinical-hold-on-immunomes-imm-bcp-01-ind-application-for-the-treatment-of-covid-19/ 2022-03-11T13:21:26+00:00 https://investors.immunome.com/immunomes-antibody-cocktail-effective-against-sars-cov-2-omicron-variant-in-in-vitro-live-virus-testing/ 2022-02-08T13:39:59+00:00 https://investors.immunome.com/immunome-provides-update-on-investigational-new-drug-application-for-imm-bcp-01-for-the-treatment-of-covid-19/ 2022-02-09T16:07:20+00:00 https://investors.immunome.com/immunome-to-participate-in-fireside-chat-hosted-by-cantor-fitzgerald/ 2022-01-05T13:42:24+00:00 https://investors.immunome.com/immunome-expects-imm-bcp-01-antibody-cocktail-to-neutralize-the-sars-cov-2-omicron-variant/ 2022-01-05T13:40:57+00:00 https://investors.immunome.com/immunome-announces-submission-of-an-investigational-new-drug-ind-application-for-imm-bcp-01-for-the-treatment-of-covid-19/ 2022-01-05T13:38:48+00:00 https://investors.immunome.com/immunome-reports-third-quarter-2021-financial-results/ 2022-01-05T13:36:21+00:00 https://investors.immunome.com/immunome-to-present-at-the-stifel-healthcare-conference/ 2022-01-05T13:34:06+00:00 https://investors.immunome.com/immunome-announces-submission-for-publication-of-pre-clinical-research-detailing-the-importance-of-antibody-cocktail-for-sars-cov-2-treatment-and-prophylaxis/ 2022-01-05T13:32:17+00:00 https://investors.immunome.com/immunome-presents-compelling-preclinical-data-on-anti-il-38-antibody-program-at-the-american-association-for-cancer-research-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeu/ 2021-10-12T20:17:51+00:00 https://investors.immunome.com/immunome-to-present-preclinical-data-on-anti-il-38-antibody-program-at-the-american-association-for-cancer-research-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ 2021-10-12T20:18:01+00:00 https://investors.immunome.com/immunome-to-present-at-the-cantor-global-healthcare-conference/ 2021-10-13T17:15:00+00:00 https://investors.immunome.com/immunome-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-and-medtech-summit/ 2021-10-13T17:15:47+00:00 https://investors.immunome.com/immunome-antibody-cocktail-imm-bcp-01-neutralizes-sars-cov-2-lambda-and-delta-plus-variants-in-pre-clinical-testing/ 2021-10-15T13:54:20+00:00 https://investors.immunome.com/immunome-reports-second-quarter-2021-financial-results/ 2021-10-15T13:55:08+00:00 https://investors.immunome.com/immunome-antibody-cocktail-imm-bcp-01-neutralizes-the-sars-cov-2-delta-variant-in-pre-clinical-testing/ 2021-10-15T13:56:58+00:00 https://investors.immunome.com/immunome-to-present-at-the-ladenburg-thalmann-2021-healthcare-conference/ 2021-10-15T13:57:42+00:00 https://investors.immunome.com/immunome-appoints-andrew-badley-m-d-to-covid-19-advisory-board/ 2021-10-15T13:58:16+00:00 https://investors.immunome.com/immunome-appoints-franklyn-g-prendergast-m-d-ph-d-to-board-of-directors/ 2021-10-15T13:58:53+00:00 https://investors.immunome.com/immunome-to-present-at-the-jefferies-virtual-healthcare-conference/ 2021-10-15T13:59:49+00:00 https://investors.immunome.com/immunome-announces-additional-4-3-million-award-by-dod-following-positive-preclinical-testing-results-on-covid-19-variants-of-concern/ 2021-10-15T14:00:33+00:00 https://investors.immunome.com/immunome-reports-first-quarter-2021-financial-results/ 2021-10-15T14:01:20+00:00 https://investors.immunome.com/immunome-announces-27-million-private-placement/ 2021-10-15T14:02:29+00:00 https://investors.immunome.com/immunome-sars-cov-2-antibody-cocktail-neutralizes-uk-south-africa-brazil-and-california-variants-in-preclinical-testing-progressing-towards-ind-filing/ 2021-10-15T14:01:54+00:00 https://investors.immunome.com/immunome-appoints-corleen-roche-as-chief-financial-officer/ 2021-10-15T14:03:19+00:00 https://investors.immunome.com/immunome-appoints-dr-dennis-giesing-as-chief-development-officer/ 2021-10-15T14:17:27+00:00 https://investors.immunome.com/immunome-reports-fourth-quarter-and-full-year-2020-financial-results-provides-corporate-update/ 2021-10-15T14:18:13+00:00 https://investors.immunome.com/immunome-advances-its-proprietary-antibody-against-il-38-a-novel-innate-immune-checkpoint-into-ind-enabling-studies/ 2021-10-15T14:26:14+00:00 https://investors.immunome.com/immunome-discovers-antibodies-capable-of-neutralizing-multiple-sars-cov-2-variants-including-the-south-african-variant-in-pseudovirus-testing/ 2021-10-15T14:26:57+00:00 https://investors.immunome.com/abzena-selected-by-immunome-to-develop-and-manufacture-antibody-cocktail-for-immunomes-covid-19-antibody-based-treatment/ 2021-10-15T14:30:49+00:00 https://investors.immunome.com/immunomes-research-reveals-a-broad-super-responder-memory-b-cell-response-to-the-sars-cov-2-virus/ 2021-10-15T14:31:26+00:00 https://news.bloomberglaw.com/us-law-week/immunome-apiject-biotechs-hire-legal-chiefs-amid-covid-19-fight?utm_source=rss 2021-10-15T14:40:12+00:00 https://investors.immunome.com/immunome-provides-organizational-update-appoints-richard-baron-to-its-board-of-directors-and-sandra-stoneman-as-chief-legal-officer-and-corporate-secretary/ 2021-10-15T14:39:28+00:00 https://investors.immunome.com/immunome-reports-third-quarter-2020-financial-results-and-significant-progress/ 2021-10-15T14:40:52+00:00 https://investors.immunome.com/immunome-announces-exercise-in-full-and-closing-of-over-allotment-option-in-initial-public-offering/ 2021-10-15T14:41:53+00:00 https://investors.immunome.com/immunome-announces-pricing-of-upsized-initial-public-offering/ 2021-10-15T14:42:38+00:00 https://investors.immunome.com/immunome-announces-creation-of-covid-19-advisory-board/ 2021-10-15T14:43:16+00:00 https://www.jpeocbrnd.osd.mil/Media/News/Article/2520071/dod-awards-industry-partner-immunome-133-million-for-biosynthetic-convalescent/ 2021-10-15T14:44:04+00:00 https://investors.immunome.com/ph-pharma-and-immunome-enter-into-collaboration-and-license-agreement-to-develop-and-commercialize-multiple-novel-antibody-drug-conjugates-in-oncology/ 2021-10-15T14:46:18+00:00 https://investors.immunome.com/immunome-appoints-purnanand-sarma-phd-as-president-and-chief-executive-officer/ 2021-10-15T14:45:36+00:00 https://investors.immunome.com/immunome-raises-5-million-series-a-financing-to-advance-novel-cancer-immunotherapies/ 2021-10-15T14:47:14+00:00 https://investors.immunome.com/immunome-appoints-michael-j-morin-phd-as-president-and-chief-scientific-officer/ 2024-12-17T20:19:00+00:00